Lilly buying developer of pain-management drugs for $960M
The Indianapolis-based drugmaker’s purchase of the biotech firm CoLucid Pharmaceuticals will give it access to a late-stage experimental medication for migraine headaches.
Drug discovery
Articles
Carmel biotech firm scores major deal with pharmaceutical giant
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
At Eli Lilly, tears, heartbreak and renewed determination
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Lilly cancer drug lands accelerated FDA approval
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Wall Street analysts jumping on Lilly train
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Clinton’s drug proposals ‘very negative’ for industry, top CEO says
The head of Pfizer Inc., America’s biggest drugmaker, said Democratic presidential nominee Hillary Clinton’s proposals to contain the price of pharmaceuticals would be “very negative” for the industry and are a step toward single-payer health care.
CEO Ellis resigns after 20 years at struggling drug firm Endocyte
The West Lafayette-based company has named CFO and COO Mike Sherman as new CEO and president, but did not give a reason for the abrupt change in leadership.
Indy drug firm scores multi-million-dollar help from NIH
Indianapolis-based Chondrial Therapeutics LLC has been accepted into a program run by the National Institutes of Health that will provide the drug company with services worth at least $5 million, the company estimates.
First-of-a-kind drug approvals continued rise in 2015
The rising figures reflect an industry-wide focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.
Deal puts IU doctor’s research on path to market
A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.
Lilly leaps into new frontier of cancer drugs
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Female libido drug nears approval with FDA panel’s backing
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
Potential Alzheimer’s drug further backs protein hypothesis
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Senate panel considers ‘right-to-try’ trial drugs bill
An Indiana Senate committee is considering a bill that would give terminally ill patients easier access to experimental drugs that have not received full federal approval. Indiana is one of nearly two dozen states that are considering the legislation.
How Eli Lilly CEO Lechleiter pulled company out of long slide
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
Novartis expects price war with Lilly over psoriasis drugs
Novartis AG is racing to establish itself in the market for new treatments for psoriasis ahead of competing drugs by Amgen Inc. and Eli Lilly and Co. in the United States.
Lilly’s Cyramza gets new marketing approval
Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
Alzheimer’s tests present dilemma of knowing the future
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
Lilly rheumatoid arthritis drug meets goals in final-stage trial
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.